| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5305109c4efec4cbcdd8bc05bdb00399 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36 |
| filingDate |
2009-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_570a7d00a3558c677b4f627cd968224d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f13aa4c7fb8aaedc90bfe30be108047e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85d18b56f5d639745d8234ae1cb1c087
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de1bc298d3330b210282b8622f0c6b0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_242f884d0ac40ad9c6bf346b9e0aa5be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba1af86076fa6f7220d5302bc3be7959 |
| publicationDate |
2011-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CZ-2009570-A3 |
| titleOfInvention |
Preparation, stabilization and use of polymorph of imatinib mesylate for the development of dosage forms |
| abstract |
The present invention relates to a process for the production of imatinib mesylate polymorphs as suitable forms of APIs for dosage forms. The formation of novel polymorphs of the tyrosine kinase inhibitor is effected by the conditions comprising the steps of: a) preparing imatinib mesylate by reacting the base of imatinib with methanesulfonic acid in an aqueous medium or in a water-organic solvent mixture with the optional addition of an organic solvent; b) adding an inorganic salt in an aqueous solution, controlling the pH and ionic strength of the solution; c) temperature controlled crystallization process. The solution also relates to the crystalline form of the polymorph of imatinib mesylate and its use. |
| priorityDate |
2009-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |